Moleculin receives Mexican patent for lung-targeted Annamycin formulation through 2040
AI Summary- Moleculin Biotech secured Mexican Patent No. 436849 for its lung-targeted liposomal Annamycin technology.
- Patent protection for the covered technology remains in force until November 23, 2040.
- MIRACLE evaluates Annamycin with cytarabine in relapsed or refractory AML patients.